Targeting the chemokine receptor CXCR2 to prevent MDSC recruitment to the tumor microenvironment has been reported to suppress metastases, improve T cell entry, and augment the efficacy of PD‐1 blockade.[22] This is consistent with our findings that the combination therapy of a CXCR2 inhibitor, AB680, and anti‐PD‐1 therapy showed superior synergistic tumor suppression and prolonged the survival of tumor‐bearing mice. This evidence concerns the gene CXCR2 and neoplasm.